These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation. Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Nail Psoriasis Targeted Therapies: A Systematic Review. Hwang JK; Ricardo JW; Lipner SR Am J Clin Dermatol; 2023 Sep; 24(5):695-720. PubMed ID: 37209391 [TBL] [Abstract][Full Text] [Related]
6. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. Whitlock SM; Enos CW; Armstrong AW; Gottlieb A; Langley RG; Lebwohl M; Merola JF; Ryan C; Siegel MP; Weinberg JM; Wu JJ; Van Voorhees AS J Am Acad Dermatol; 2018 Feb; 78(2):383-394. PubMed ID: 29332708 [TBL] [Abstract][Full Text] [Related]
7. Full Guidelines-From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis. James WA; Rosenberg AL; Wu JJ; Hsu S; Armstrong A; Wallace EB; Lee LW; Merola J; Schwartzman S; Gladman D; Liu C; Koo J; Hawkes JE; Reddy S; Prussick R; Yamauchi P; Lewitt M; Soung J; Weinberg J; Lebwohl M; Glick B; Kircik L; Desai S; Feldman SR; Zaino ML J Am Acad Dermatol; 2024 Aug; 91(2):251.e1-251.e11. PubMed ID: 38499181 [TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis. Lu C; Wallace BI; Waljee AK; Fu W; Zhang Q; Liu Y Semin Arthritis Rheum; 2019 Dec; 49(3):381-388. PubMed ID: 31272807 [TBL] [Abstract][Full Text] [Related]
9. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies. Elyoussfi S; Thomas BJ; Ciurtin C Rheumatol Int; 2016 May; 36(5):603-12. PubMed ID: 26892034 [TBL] [Abstract][Full Text] [Related]
10. A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. Baumrin E; Van Voorhees A; Garg A; Feldman SR; Merola JF J Am Acad Dermatol; 2019 Jul; 81(1):102-110. PubMed ID: 30885757 [TBL] [Abstract][Full Text] [Related]
11. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis. Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents. Gan EY; Chong WS; Tey HL BioDrugs; 2013 Aug; 27(4):359-73. PubMed ID: 23580094 [TBL] [Abstract][Full Text] [Related]
13. Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation. Crowley JJ; Weinberg JM; Wu JJ; Robertson AD; Van Voorhees AS; JAMA Dermatol; 2015 Jan; 151(1):87-94. PubMed ID: 25471223 [TBL] [Abstract][Full Text] [Related]
14. Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis. Yiu ZZN; Becher G; Kirby B; Laws P; Reynolds NJ; Smith CH; Warren RB; Griffiths CEM; JAMA Dermatol; 2022 Oct; 158(10):1131-1141. PubMed ID: 35791876 [TBL] [Abstract][Full Text] [Related]
15. Dermatology patients on biologics and certain other systemic therapies should receive a "booster" messenger RNA COVID-19 vaccine dose: A critical appraisal of recent Food and Drug Administration and Advisory Committee on Immunization Practices recommendations. Waldman RA; Grant-Kels JM J Am Acad Dermatol; 2021 Nov; 85(5):1113-1116. PubMed ID: 34437985 [No Abstract] [Full Text] [Related]
16. Drugs for psoriasis. Med Lett Drugs Ther; 2019 Jun; 61(1574):89-96. PubMed ID: 31381544 [No Abstract] [Full Text] [Related]
17. Biologics combined with conventional systemic agents for the treatment of children with severe psoriasis. Real-life data from the BiPe cohorts and a practice survey among French and Italian pediatric dermatologists. Mahé E; Beauchet A; Hadj-Rabia S; Mazereeuw-Hautier J; Mallet S; Phan A; Severino-Freire M; Boralevi F; Aubert H; Barthélémy H; Girard C; Martin L; Piram M; Barbarot S; Balguerie X; Zitouni J; Phan C; Di Lernia V; Dermatol Ther; 2022 Nov; 35(11):e15828. PubMed ID: 36107157 [TBL] [Abstract][Full Text] [Related]
18. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis. Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538 [TBL] [Abstract][Full Text] [Related]
19. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. Gelfand JM; Armstrong AW; Bell S; Anesi GL; Blauvelt A; Calabrese C; Dommasch ED; Feldman SR; Gladman D; Kircik L; Lebwohl M; Lo Re V; Martin G; Merola JF; Scher JU; Schwartzman S; Treat JR; Van Voorhees AS; Ellebrecht CT; Fenner J; Ocon A; Syed MN; Weinstein EJ; Gondo G; Heydon S; Koons S; Ritchlin CT J Am Acad Dermatol; 2021 May; 84(5):1254-1268. PubMed ID: 33422626 [TBL] [Abstract][Full Text] [Related]
20. 2023 guidelines on the management of psoriasis by the Dermatological Society of Singapore. Oon HH; Tan C; Aw DCW; Chong WS; Koh HY; Leung YY; Lim KS; Pan JY; Tan ES; Tan KW; Tham SN; Theng C; Wong SN Ann Acad Med Singap; 2024 Sep; 53(9):562-577. PubMed ID: 39373375 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]